E P Therapeutics, Inc, Waterford, 06385, CT, USA,
Cytotechnology. 2004 Jul;45(3):117-23. doi: 10.1007/s10616-004-6402-8.
A process of producing a receptor in HEK-293 cells used for the drug discovery program at Pfizer Inc. has been successfully developed with a novel BelloCell bioreactor to replace the conventional 2-D cell culturing devices including Cell Factories and roller bottles. A single BelloCell-500 has produced >1.4 x 10(9) HEK-293 cells, which are equivalent to those produced by 12 roller bottles, with substantially easier operation, single inoculation, less inoculum, less medium consumption and better space utilization. The receptor expression levels are better than those obtained by the traditional process. 3.7 pmoles of radioligandY mg(-1) protein were attained in the bioreactor compared to 2.3 pmoles of radioligandY mg(-1) protein in roller bottles. This may be attributed to the three dimensional attachment during cell growth. A 92% cell recovery from the bioreactor has been attained using Acutase or Trypsin treatment followed by four washes. It has been proven to be a viable and efficient device to produce adherent cells and express target components of interest for drug discovery applications.
一种用于辉瑞公司药物发现计划的在 HEK-293 细胞中产生受体的方法已经成功开发,使用新型的 BelloCell 生物反应器替代传统的 2-D 细胞培养设备,包括细胞工厂和滚瓶。单个 BelloCell-500 产生的 >1.4 x 10(9)HEK-293 细胞,相当于 12 个滚瓶产生的细胞,操作更简单、只需一次接种、接种量更少、培养基消耗更少、空间利用率更高。受体表达水平优于传统工艺获得的水平。与滚瓶中 2.3 pmoles 的放射性配体 Y mg(-1)蛋白相比,生物反应器中获得了 3.7 pmoles 的放射性配体 Y mg(-1)蛋白。这可能归因于细胞生长过程中的三维附着。使用 Acutase 或胰蛋白酶处理并进行四次洗涤,从生物反应器中获得了 92%的细胞回收率。事实证明,该生物反应器是一种可行且高效的设备,可用于生产贴壁细胞,并表达药物发现应用中感兴趣的靶标成分。